Very interesting summary article on therapeutic cancer vaccines and their mechanisms of action. Principles of action and immunological backgrounds are discussed. The article explains very well the immunological mode of action of peptide-based cancer vaccines.
With our product candidate VCC-001, we belong to this class and also have the potential to vaccinate against all patient-relevant neoantigens and antigens based on its autologous nature.
